On January 23, 2026, BioCryst Pharmaceuticals signed a $400 million loan agreement to finance a merger with Astria Therapeutics, where each Astria share will convert to 0.59 shares of BioCryst and $8.55 in cash. This event is significant, indicating a positive sentiment for investors, as it supports major expansion efforts.